A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced or Metastatic Breast Cancer
Interventions: DRUG: MRG002
Sponsor: Shanghai Miracogen Inc.